Murine models in mantle cell lymphoma.
Mantle cell lymphoma (MCL), an aggressive, heterogeneous B-cell lymphoma associated with a relatively short survival has been challenging to study in the laboratory due to the lack of in vitro and in vivo models that accurately recapitulate the disease. Advancement has been made in the characterization of MCL cell lines through the generation of the ATCC MCL bank, enabling their use in xenograft murine models. These models provide valuable but limited information for the preclinical evaluation and development of targeted therapies for MCL despite their deficiencies of a functioning immune system and correct micro-environment. Currently, there is only one double transgenic murine model known to develop spontaneous MCL. There is an urgency to develop innovative transgenic murine models that could be used to better predict therapeutic responses and precisely decipher mechanisms of action, to foster refinement of novel therapeutics for mantle cell lymphoma.
Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA.
Kelly
K
Zullo
Jennifer E
JE
Amengual
Owen A
OA
O'Connor
Luigi
L
Scotto
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018070:Biological Specimen Banks; D045744:Cell Line, Tumor / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D017930:Genes, Reporter; D006801:Humans; D008156:Luciferases; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D057054:Molecular Imaging; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D008156:Luciferases